Form 4: Terns Pharma CMO Sells Shares for Tax Obligations

Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, sold 1,155 shares of common stock on January 2, 2026, to cover tax liabilities from restricted stock unit vesting.

Summary

• Emil Kuriakose, Chief Medical Officer of Terns Pharmaceuticals, Inc. (TERN), reported the sale of common stock.
• The transactions occurred on January 2, 2026, and were executed under a Rule 10b5-1(c) plan.
• A total of 200 shares were sold at a weighted average price of $39.6 per share, with prices ranging from $39.25 to $39.95.
• An additional 955 shares were sold at a weighted average price of $38.3586 per share, with prices ranging from $38.25 to $38.73.
• The sales were non-discretionary and solely for the purpose of satisfying tax obligations associated with the vesting of a restricted stock unit award.
• Following these transactions, Emil Kuriakose beneficially owns 50,365 shares of common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary sale of shares by an insider to cover tax obligations from RSU vesting. This is a neutral event and does not indicate any positive or negative sentiment regarding the company's performance or prospects.

Positives

• The sales were non-discretionary and for tax purposes, indicating no change in management's fundamental view of the company.
• The transactions were conducted under a Rule 10b5-1(c) plan, suggesting pre-planned sales rather than reactive trading.

Negatives

• No specific negative points are indicated by this routine tax-related sale.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Routine insider sales for tax purposes, such as those reported in this Form 4, are common across all industries and typically do not reflect specific industry trends or competitive positioning. They are a standard part of executive compensation and tax planning.

Stakeholder Impact

• Shareholders: The sale of 1,155 shares by a Chief Medical Officer is a minor dilution relative to the total outstanding shares and is unlikely to have a significant impact on shareholder value or perception, given its non-discretionary nature for tax purposes.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an executive to cover tax liabilities from vested restricted stock units. Such transactions are common and do not typically reflect a change in the executive's confidence in the company or its future prospects. Therefore, it provides no new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Terns Pharmaceuticals, TERN, Form 4, Insider Trading, Stock Sale, Chief Medical Officer, Restricted Stock Units, Tax Obligations, Rule 10b5-1